ArticleEndocrine oncology (Bristol, England)2025
Prevalence of growth hormone deficiency in brain tumor survivors: a systematic review and meta-analysis.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the prevalence of growth hormone deficiency in patients who underwent cranial irradiation for brain tumors. Methods: Ovid Medline and Embase databases were used for review. Eligible studies were observational studies with brain tumor survivors who had growth hormone function evaluated after treatment at age ≥18 years. Patient data on disease prevalence were pooled using the random-effect, generic inverse variance method. The presence of publication bias was determined by Egger's test. Mann-Whitney U test, univariate and multivariate linear regression were used to determine the association and effect of covariates and growth hormone peak level. Results: After screening 3,355 relevant articles, seven studies were included. The pooled result showed that out of 3,489 patients who received radiation for brain tumors, regardless of age at the time of treatment, 50% developed growth hormone deficiency (95% CI 40-60%, Conclusions: Half of brain tumor survivors develop growth hormone deficiency. A longer duration of follow-up is associated with higher risks of growth hormone deficiency. Lifelong follow-up is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.